Trial Profile
Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 13 Sep 2011 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 09 Mar 2011 Planned initiation date changed from Sep 2010 to Jun 2011 as reported by ClinicalTrials.gov.